Replimune Valuation
| REPL Stock | USD 13.26 1.67 11.19% |
At this time, the company appears to be undervalued. Replimune Group holds a recent Real Value of $22.89 per share. The prevailing price of the company is $13.26. Our model determines the value of Replimune Group from analyzing the company fundamentals such as Return On Equity of -0.5, shares owned by institutions of 95.29 %, and Shares Outstanding of 68.42 M as well as examining its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Replimune's valuation include:
Price Book 2.6778 | Enterprise Value 551.3 M | Enterprise Value Ebitda (0.24) |
Undervalued
Today
Please note that Replimune's price fluctuation is somewhat reliable at this time. Calculation of the real value of Replimune Group is based on 3 months time horizon. Increasing Replimune's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Replimune stock is determined by what a typical buyer is willing to pay for full or partial control of Replimune Group. Since Replimune is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Replimune Stock. However, Replimune's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 13.26 | Real 22.89 | Target 52.11 | Hype 13.41 | Naive 13.66 |
The intrinsic value of Replimune's stock can be calculated using various methods such as discounted cash flow or dividend analysis. That value may differ from its market price, which is determined by factors such as investor sentiment, market trends, headlines, and other external factors that may influence Replimune's stock price.
Estimating the potential upside or downside of Replimune Group helps investors to forecast how Replimune stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Replimune more accurately as focusing exclusively on Replimune's fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Replimune's intrinsic value based on its ongoing forecasts of Replimune's financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Replimune's closest peers.
Replimune Cash |
|
Replimune Valuation Trend
Knowing Replimune's actual value is paramount for traders when making sound investment determinations. Using both Replimune's enterprise value as well as its market capitalization is the best way to estimate the value of the company and is usually enough for investors to make market timing decisions.
Replimune Total Value Analysis
Replimune Group is at this time projected to have valuation of 551.28 M with market capitalization of 907.21 M, debt of 75.87 M, and cash on hands of 395.08 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Replimune fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
551.28 M | 907.21 M | 75.87 M | 395.08 M |
Replimune Asset Utilization
One of the ways to look at asset utilization of Replimune is to check how much profit was generated for every dollar of assets it reports. Replimune holds a negative application of assets of -0.27 pct., losing $0.002707 for each dollar of assets held by the company. Inadequate asset utilization implies the company is being less effective with each dollar of assets it holds. Put it differently, asset utilization of Replimune Group shows how discouraging it operates for each dollar spent on its assets.Replimune Ownership Allocation
The majority of Replimune Group outstanding shares are owned by third-party entities. These institutional holders are usually referred to as non-private investors looking to secure positions in Replimune Group to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Replimune. Please pay attention to any change in the institutional holdings of Replimune Group as this could imply that something significant has changed or is about to change at the company.Replimune Profitability Analysis
Net Loss for the year was (215.79 M) with profit before overhead, payroll, taxes, and interest of 0.About Replimune Valuation
We use absolute and relative valuation methodologies to arrive at the intrinsic value of Replimune Group. In general, an absolute valuation paradigm, as applied to this company, attempts to find the value of Replimune Group based exclusively on its fundamental and basic technical indicators. By analyzing Replimune's financials, quarterly and monthly indicators, and their related drivers, we attempt to find the most accurate representation of Replimune's intrinsic value. As compared to an absolute model, our relative valuation model uses a comparative analysis of Replimune. We calculate exposure to Replimune's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Replimune's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | -2.7 M | -2.8 M |
Replimune Growth Indicators
Investing in growth stocks can be very risky. If the company such as Replimune does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 66.6 M |
Replimune Current Valuation Indicators
Replimune's valuation analysis is a process of estimating the intrinsic value of all assets and outstanding equities. There are different methodologies and models we use to develop the final Replimune's valuation. The techniques such as discounted cash flow and fundamental indicators such as book value per share or market capitalization are well known and widely used across most financial advisers and money managers.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Replimune, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Replimune's valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Replimune's worth.When determining whether Replimune Group is a strong investment it is important to analyze Replimune's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Replimune's future performance. For an informed investment choice regarding Replimune Stock, refer to the following important reports: Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Replimune Group. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey. You can also try the Portfolio Rebalancing module to analyze risk-adjusted returns against different time horizons to find asset-allocation targets.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Replimune. If investors know Replimune will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Replimune listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (3.04) | Return On Assets (0.27) | Return On Equity (0.50) |
The market value of Replimune Group is measured differently than its book value, which is the value of Replimune that is recorded on the company's balance sheet. Investors also form their own opinion of Replimune's value that differs from its market value or its book value, called intrinsic value, which is Replimune's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Replimune's market value can be influenced by many factors that don't directly affect Replimune's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Replimune's value and its price as these two are different measures arrived at by different means. Investors typically determine if Replimune is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Replimune's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.